MX2011011596A - Perifosina y capecitabina como un tratamiento combinado para cancer. - Google Patents

Perifosina y capecitabina como un tratamiento combinado para cancer.

Info

Publication number
MX2011011596A
MX2011011596A MX2011011596A MX2011011596A MX2011011596A MX 2011011596 A MX2011011596 A MX 2011011596A MX 2011011596 A MX2011011596 A MX 2011011596A MX 2011011596 A MX2011011596 A MX 2011011596A MX 2011011596 A MX2011011596 A MX 2011011596A
Authority
MX
Mexico
Prior art keywords
perifosine
capecitabine
cancer
combined treatment
treatment
Prior art date
Application number
MX2011011596A
Other languages
English (en)
Inventor
Enrique Poradosu
Peter Sportelli
Original Assignee
Keryx Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keryx Biopharmaceuticals Inc filed Critical Keryx Biopharmaceuticals Inc
Publication of MX2011011596A publication Critical patent/MX2011011596A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Abstract

Aquí se describen regímenes de tratamiento que comprenden tratamiento concomitante de cáncer, con perifosina y capecitabina, así como composiciones farmacéuticas y sus formas de dosis unitaria, formuladas para ser adecuadas para uso en los regímenes de tratamiento.
MX2011011596A 2010-03-31 2011-03-31 Perifosina y capecitabina como un tratamiento combinado para cancer. MX2011011596A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31931510P 2010-03-31 2010-03-31
PCT/US2011/030800 WO2011123691A1 (en) 2010-03-31 2011-03-31 Perifosine and capecitabine as a combined treatment for cancer

Publications (1)

Publication Number Publication Date
MX2011011596A true MX2011011596A (es) 2012-02-01

Family

ID=44202913

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011596A MX2011011596A (es) 2010-03-31 2011-03-31 Perifosina y capecitabina como un tratamiento combinado para cancer.

Country Status (4)

Country Link
US (1) US8383607B2 (es)
CA (1) CA2794513A1 (es)
MX (1) MX2011011596A (es)
WO (1) WO2011123691A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8383605B2 (en) 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
JP2005535688A (ja) 2002-07-30 2005-11-24 ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗腫瘍医薬との組合せにおけるアルキルホスホコリンの使用
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
WO2013106175A1 (en) 2011-12-19 2013-07-18 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
AR074397A1 (es) 2008-11-26 2011-01-12 Amgen Inc Polipéptidos receptores de activina iib estabilizados y usos de los mismos
CA2794513A1 (en) 2010-03-31 2011-10-06 Aeterna Zentaris Gmbh Perifosine and capecitabine as a combined treatment for cancer
GB201115211D0 (en) * 2011-09-02 2011-10-19 Slotervaart Participaties Bv Composition
KR20150136061A (ko) * 2013-02-01 2015-12-04 산타 마리아 바이오테라퓨틱스, 인코포레이티드 대상에 항-액티빈-a 화합물의 투여
RU2019126572A (ru) * 2017-02-06 2021-03-09 Интас Фармасьютикалс Лтд. Композиция, содержащая капецитабин немедленного высвобождения и капецитабин замедленного высвобождения
WO2023187037A1 (en) 2022-03-31 2023-10-05 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
WO2024083716A1 (en) 2022-10-17 2024-04-25 Astrazeneca Ab Combinations of a serd for the treatment of cancer

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE136783T1 (de) 1991-07-04 1996-05-15 Asta Medica Ag Arzneimittel mit antineoplastischer wirkung enthaltend als wirkstoff octadecyl-(2-(n- methylpiperidino)-ethyl>-phosphat und verfahren zu dessen herstellung
US5942639A (en) 1991-07-04 1999-08-24 Asta Medica Aktiengesellschaft Process for the preparation of alkylphosphocholines and the production thereof in pure form
US6172050B1 (en) 1992-07-11 2001-01-09 Asta Medica Aktiengesellschaft Phospholipid derivatives
DE19650778C2 (de) 1996-12-06 2001-01-04 Asta Medica Ag Verwendung von Dopaminrezeptor-Antagonisten in der palliativen Tumortherapie
TR200001717T2 (tr) 1998-01-22 2000-11-21 Asta Medica Aktiengesellschaft Leishmaniasis tedavisinde miltefosin ihtiva eden ve ağızdan alınan katı farmasötik bileşimler.
EP1135193B1 (de) 1998-12-04 2002-10-30 Max-Delbrück-Centrum Für Molekulare Medizin Mittel zur tumortherapie auf liposomenbasis, die tamoxifen enthalten
CA2356736A1 (en) 1998-12-21 2000-06-29 Inkeysa. S.A. Use of etherlysophospholipids as antiinflammatory agents
CN104274442A (zh) 2001-02-19 2015-01-14 诺华股份有限公司 癌症的治疗
WO2002076472A2 (en) 2001-03-23 2002-10-03 Shire Biochem Inc. Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs
SI1461083T1 (sl) 2002-01-02 2006-08-31 Nerviano Medical Sciences Srl Kombinirana terapija proti tumorjem na osnovi substituiranih akriloil distamicinskih derivatov in inhibitorjev protein-kinaze (serin/treonin-kinaze)
MXPA04011310A (es) 2002-05-17 2005-02-14 Celgene Corp Metodo y composiciones que utilizan farmacos inhibidores selectivos de citocinas para el tratamiento y el manejo de canceres y otras enfermedades.
US6538029B1 (en) 2002-05-29 2003-03-25 Cell Pathways Methods for treatment of renal cell carcinoma
US8383605B2 (en) 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
JP2005535688A (ja) 2002-07-30 2005-11-24 ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗腫瘍医薬との組合せにおけるアルキルホスホコリンの使用
WO2005000318A2 (en) 2003-06-23 2005-01-06 Neopharm, Inc. Method of inducing apoptosis and inhibiting cardiolipin synthesis
US7399484B2 (en) 2004-06-30 2008-07-15 Kimberly-Clark Worldwide, Inc. System and method for providing therapy to an individual
WO2006081452A2 (en) 2005-01-28 2006-08-03 Robert Birch Co-administration of perifosine with chemotherapeutics
WO2006097323A1 (en) * 2005-03-18 2006-09-21 Lutz Weber TETRAHYDRO-ISOQUINOLIN-l-ONES FOR THE TREATMENT OF CANCER
WO2007011721A1 (en) * 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
WO2008034039A2 (en) * 2006-09-15 2008-03-20 Nexuspharma Inc. Novel tetrahydro-isoquinolines
US20100272717A1 (en) * 2007-12-13 2010-10-28 Novartis Ag Combinations of therapeutic agents for treating cancer
CA2794513A1 (en) 2010-03-31 2011-10-06 Aeterna Zentaris Gmbh Perifosine and capecitabine as a combined treatment for cancer

Also Published As

Publication number Publication date
WO2011123691A1 (en) 2011-10-06
US20110243933A1 (en) 2011-10-06
US8383607B2 (en) 2013-02-26
CA2794513A1 (en) 2011-10-06

Similar Documents

Publication Publication Date Title
MX2011011596A (es) Perifosina y capecitabina como un tratamiento combinado para cancer.
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
IN2012DN06720A (es)
PH12014501561A1 (en) Therapeutically active compounds and their methods of use
IL231536A (en) Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
GB201106743D0 (en) Novel compounds
NZ631144A (en) Compositions and methods for transmucosal absorption
GB201118656D0 (en) New compounds
HUE043540T2 (hu) Szubsztituált dimer kinazolin-származék, elõállítása, valamint alkalmazása 1-es és 2-es típusú cukorbetegség kezelésére szolgáló gyógyászati készítményekben
GB201111485D0 (en) Drug composition and its use in therapy
PH12014501639A1 (en) Pharmaceutical compositions and methods
CL2013000016A1 (es) Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
MX2019000225A (es) Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
BR112012016543A2 (pt) Tratamento com vb-201
MX2013006319A (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek.
WO2012061390A3 (en) Therapeutic compositions and methods
MX354383B (es) Sistemas, métodos y formulaciones para tratamiento de cáncer.
MX2019008817A (es) Formulacion de liberacion prolongada para reducir la frecuencia de miccion y metodo de uso de la misma.
CL2013001445A1 (es) Compuestos derivados de difenilamina; composicion farmaceutica y uso en el tratamiento de enfermedades inflamatorias, tales como cancer.
WO2013096335A8 (en) ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT
MX354667B (es) Metodos para el tratamiento de un impedimento sensorial-motriz relacionado con el accidente cerebrovascular con el uso de aminopiridinas.
CR20130488A (es) Derivados de tieno [2,3-d]pirimidina y su uso para tratar arritmia
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
UA44395U (ru) Применение тиоцетама в качестве диуретического средства с мягким мочегонным действием в комплексном лечении
TN2013000247A1 (en) Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: AETERNA ZENTARIS GMBH

FG Grant or registration